ライフサイエンスコーパス: interleukin-12

1 or necrosis factor alpha, interleukin-6, and interleukin-12).

2 or necrosis factor alpha, interleukin 6, and interleukin 12.

3 itric oxide, tumor necrosis factor alpha, or interleukin-12.

4 naling of proinflammatory cytokines, such as interleukin-12.

5 TRIF, and induction of interferon-gamma and interleukin-12.

6 pha, monocyte chemoattractant protein-1, and interleukin-12.

7 helminth antigens generally fail to produce interleukin-12.

8 en naive CD8+ T cells are stimulated without interleukin-12.

9 ivated in vitro with mouse thyroglobulin and interleukin-12.

10 ired gamma interferon but was independent of interleukin-12.

11 ctivated dendritic cells producing IFN-I and interleukin-12.

12 anulocyte colony-stimulating factor (G-CSF), interleukin-12/23 (IL-12/23), and IL-13 trended signific

13 nderwent randomization to treatment with the interleukin-12/23 monoclonal antibody (one 45-mg dose, o

14 occurred in 79% of patients treated with the interleukin-12/23 monoclonal antibody as compared with 7

15 bo crossed over to receive one 90-mg dose of interleukin-12/23 monoclonal antibody at week 20.

16 demonstrates the therapeutic efficacy of an interleukin-12/23 monoclonal antibody in psoriasis and p

17 evaluated the safety and efficacy of a human interleukin-12/23 monoclonal antibody in treating psoria

18 Patients assigned to the interleukin-12/23 monoclonal antibody received one addit

19 in 52% of patients who received 45 mg of the interleukin-12/23 monoclonal antibody, in 59% of those w

20 d provides further evidence of a role of the interleukin-12/23 p40 cytokines in the pathophysiology o

21 noclonal antibody against the p40 subunit of interleukin-12/23.

22 on dendritic cells; increased production of interleukin-12/23p40 (IL-12/23p40), gamma interferon (IF

23 erbated production of dendritic-cell-derived interleukin-12/23p40 and tumour necrosis factor-alpha, i

24 ic signs of colon inflammation, secretion of interleukin-12/23p40 in colonic explant cultures, serolo

25 We demonstrate that interleukin-12, a heterodimeric pro-inflammatory cytokin

26 Herein, we showed interleukin-12 acting via the transcription factor STAT4

27 g a recombinant adenovirus vector expressing interleukin-12 (Ad5IL-12) to target natural killer (NK)

28 d gene 3 (Ebi3, which encodes IL-27beta) and interleukin-12 alpha (Il12a, which encodes IL-12alpha/p3

29 timulate immature dendritic cells to secrete interleukin 12 and induce IFN-gamma in peripheral blood

30 Human interleukin 12 and interleukin 23 (IL12/23) influence su

31 like receptor (TLR) stimulation resulting in interleukin 12 and other inflammatory cytokine expressio

32 lated with an increase in H. pylori-specific interleukin-12 and both immunoglobulin G1 (IgG1) and IgG

33 ficient mice, upregulating the expression of interleukin-12 and costimulatory molecules on those cell

34 els of inflammation) by high availability of interleukin-12 and IFN-gamma, ultimately leading to comp

35 ogether with the IFN-gamma-inducing cytokine interleukin-12 and IFN-gamma-inducible chemokines such a

36 ceptor (TCR) signaling and cytokines such as interleukin-12 and interferon gamma (IFN-gamma).

37 of the ability of dendritic cells to induce interleukin-12 and interferon-beta in the context of bot

38 l inflammatory disease can occur with excess interleukin-12 and interferon-gamma production alone and

39 cruitment to the joint, orchestrated through interleukin-12 and interferon-gamma.

40 roinflammatory cytokine induction (including interleukin-12 and interleukin-18), but was bereft of in

41 interferon gamma by NK cells in response to interleukin-12 and interleukin-18, providing a mechanist

42 , they are less responsive to stimulation by interleukin-12 and interleukin-18.

43 Interleukin-12 and interleukin-23 are inflammatory cytok

44 ompared two biologic agents, ustekinumab (an interleukin-12 and interleukin-23 blocker) and etanercep

45 oted Toll-like receptor-induced secretion of interleukin-12 and interleukin-23 by DCs in an autocrine

46 Cytokines interleukin-12 and interleukin-23 have been implicated i

47 nterleukin-23 signaling, and ustekinumab, an interleukin-12 and interleukin-23 inhibitor, in patients

48 kinumab, an antagonist of the p40 subunit of interleukin-12 and interleukin-23, as induction and main

49 kinumab, a human monoclonal antibody against interleukin-12 and interleukin-23, is unknown.

50 a monoclonal antibody to the p40 subunit of interleukin-12 and interleukin-23, was evaluated as an i

51 ed from MS patients produce higher levels of interleukin-12 and interleukin-6, whereas pDCs account f

52 lysis of the immunostimulatory properties of interleukin-12 and its derivatives surprisingly revealed

53 0 macrophages showed increased production of interleukin-12 and nitric oxide but reduced interleukin-

54 ng motion, podosome formation, production of interleukin-12 and other cytokines, and presentation of

55 e receptor-mediated stimulation by producing interleukin-12 and process and present antigen.

56 of key proinflammatory cytokines, including interleukin-12 and the chemokine MCP-1, both known to co

57 binds the p40 subunit of interleukin-23 and interleukin-12 and thereby blocks the activity of these

58 s in part through differential regulation of interleukin-12 and transforming growth factor beta produ

59 mpanied by elevated production of DC-derived interleukin-12 and tumor necrosis factor-alpha.

60 Interleukins 12 and 23 have important roles in the patho

61 Findings suggest that interleukins 12 and 23 might affect clinical symptoms an

62 noclonal antibody against the p40 subunit of interleukins 12 and 23, ustekinumab, were used to treat

63 ytokines such as type I interferons (IFN-I), interleukin 12, and gamma interferon.

64 Nod1 stimulation did not induce TNFalpha, interleukin 12, and interferon gamma, suggesting that th

65 or necrosis factor alpha, interleukin 1beta, interleukin 12, and interleukin 17; the chemokines CCL2,

66 oinflammatory cytokines, including IFNgamma, interleukin 12, and interleukin 2 in plasma of Pip4k2c(-

67 mma when stimulated with IL-18 combined with interleukin 12, and the latter was expressed in vivo dur

68 ction showed higher levels of interleukin-4, interleukin-12, and eotaxin mRNA expression, whereas sig

69 nificantly higher T-helper (Th) 1 cytokines, interleukin-12, and interferon-gamma.

70 ne pathway, and the cytokines interleukin-7, interleukin-12, and interleukin-15 indicate that these s

71 g TLR4 expression and intensifies TNF-alpha, interleukin-12, and matrix metalloproteinase-9 productio

72 otein-1-gamma, B-lymphocyte chemoattractant, interleukin-12, and subsequent circulation helper T cell

73 f tumor necrosis factor alpha (TNFalpha) and interleukin-12, and up-regulation of vascular endothelia

74 Silencing Foxo1 ablated interleukin-12- and rapamycin-enhanced CD8(+) T cell mem

75 These mice were treated with either anti-interleukin-12 (anti-IL-12)/23p40 antibody or murine TNF

76 ses of CTLA-4(+/+)Tc0 CTL, generated without interleukin-12, are hypoproliferative within the cardiac

77 riments and cytokine substitution identified interleukin-12 as a critical mediator in regulation of p

78 teritidis) infection covering 15 years in an interleukin-12 beta1 receptor-deficient individual that

79 y-promoting cytokine secretion, particularly interleukin-12, both of which were independently trigger

80 d elevated secretion of gamma interferon and interleukin-12, but no interleukin-4, suggesting an indu

81 d production of the STAT1-dependent cytokine interleukin-12 by dendritic cells and increased parasite

82 e production of the proinflammatory cytokine interleukin-12 by dendritic cells in response to invadin

83 cytes from OVA-sensitized mice secreted more interleukin-12 compared with gal3(+/+) splenocytes.

84 rgeting CTLA-4 solely or in conjunction with interleukin-12 could influence effector CD8+ T cell resp

85 tion was associated with increased levels of interleukin-12, decreased levels of CCL4, increased chem

86 s examining the integrated role of dll4 with interleukin-12 demonstrated that, together, both of thes

87 agic pathogens, probably because of impaired interleukin 12-dependent interferon gamma production.

88 restored the efficacy of PD-1 blockade in an interleukin-12-dependent manner by increasing the recrui

89 ession, thereby showing the importance of an Interleukin-12-dependent, Interferon-gamma-independent s

90 acid-sensing TLR3, TLR7 and TLR9 in inducing interleukin 12, development of a TH1 response, and resis

91 acellular adenosine triphosphate accelerated interleukin-12-driven IFN-gamma production by liver ILC1

92 Crohn's disease inflammation is caused by an interleukin-12-driven Th1 response, which resulted in th

93 ent activation/maturation with high CD86 and interleukin-12 expression.

94 is armed with an immunomodulatory cytokine, interleukin 12 (G47-mIL12).

95 henotype as indicated by increased levels of interleukin-12, gamma interferon, and inducible nitric o

96 ociated secretory phenotypes (interleukin-8, interleukin-12, GRO, and MDC).

97 Human interleukin-12 (hIL-12) is a heparin-binding cytokine wh

98 ed significantly higher expression levels of interleukin 12, IFN-gamma, and chemokines (IP-10/CXCL-10

99 Levels of Th1 cytokines, including interleukin 12, IFN-gamma, TNFalpha, and the Th1-associa

100 ory M1-phenotype with enhanced expression of interleukin-12, IFNgamma, and SDF-1alpha and increased N

101 ed to an immunostimulatory cytokine, such as interleukin 12 (IL-12) (rNDV-anti-CD28-murine IL-12 [mIL

102 n led to a rapid increase in serum levels of interleukin 12 (IL-12) and gamma interferon (IFN-gamma).

103 t most returned to baseline by 28 dpi except interleukin 12 (IL-12) and gamma interferon.

104 of apoptosis and/or increased production of interleukin 12 (IL-12) and granulocyte-macrophage colony

105 Cytokines such as interleukin 12 (IL-12) and IL-18 are critical regulators

106 Interleukin 12 (IL-12) and IL-18 regulated this conversi

107 The proinflammatory cytokines interleukin 12 (IL-12) and IL-23 connect innate response

108 ndii stimulates production of high levels of interleukin 12 (IL-12) and interferon gamma (IFN-gamma)

109 ng BAFF or APRIL multitrimers, together with interleukin 12 (IL-12) and membrane-bound HIV-1 Env gp14

110 However, this subset did not produce interleukin 12 (IL-12) but upregulated CD103, which is e

111 The interleukin 12 (IL-12) DNA plasmid expresses human IL-12

112 ere we show that intravaginally administered interleukin 12 (IL-12) encapsulated in sustained-release

113 The interleukin 12 (IL-12) family is unique in having the on

114 r complexity and biological relevance is the interleukin 12 (IL-12) family.

115 Expression of interleukin 12 (IL-12) from NV1042 virus, a derivative o

116 ssion of the cellular hematopoietic cytokine interleukin 12 (IL-12) in HCMV-infected cells but not in

117 Furthermore, IgA(-/-) mice displayed reduced interleukin 12 (IL-12) levels at early time points, and

118 s, blocking gamma interferon (IFN-gamma) and interleukin 12 (IL-12) p40 release but promoting IL-4, I

119 AC/Env) or DNA encoding SIVenv/SIVGag/rhesus interleukin 12 (IL-12) plus SIV(M766&CG7V) gD-gp120 prot

120 Whereas interleukin 12 (IL-12) produced by antigen-presenting ce

121 e activating DC stimulus and led to enhanced interleukin 12 (IL-12) production and T-cell responses o

122 eviously found that treatment with exogenous interleukin 12 (IL-12) protects against F. tularensis in

123 A potential mechanism is the reduction of interleukin 12 (IL-12) secretion during acute measles, r

124 ia enhanced gamma interferon (IFN-gamma) and interleukin 12 (IL-12) secretion; however, the mechanism

125 gamma interferon (IFN-gamma), and an innate interleukin 12 (IL-12) signal from infected MPhi.

126 mice produced significantly more TNF-alpha, interleukin 12 (IL-12), and IL-18 in response to P. cari

127 nterleukin 6 (IL-6), interleukin 10 (IL-10), interleukin 12 (IL-12), and tumor necrosis factor alpha

128 by significant gamma interferon (IFN-gamma), interleukin 12 (IL-12), IL-2, IL-10, and IL-17 productio

129 The receptors for interleukin 12 (IL-12), IL-4 and IL-6 are required for d

130 Although serum levels of interleukin 12 (IL-12), IL-6, tumor necrosis factor alph

131 ection (postimmunization) is increased in an interleukin 12 (IL-12)-dependent manner.

132 set of T-helper 2 immunity in the absence of interleukin 12 (IL-12).

133 mmatory cytokines and chemokines, especially interleukin 12 (IL-12).

134 trations of interferon gamma (IFN-gamma) and interleukin 12 (IL-12).

135 berculosis, underlined the importance of the interleukin 12 (IL-12)/interferon gamma (IFN-gamma) circ

136 host IFN-gamma and that this is mediated by interleukin-12 (IL-12) activation of NK cells.

137 e, CEA] inhibit the secretion of the dimeric interleukin-12 (IL-12) alphabeta and beta2 forms with id

138 ive resistance was associated with increased interleukin-12 (IL-12) and decreased IL-10 pulmonary lev

139 arch were to characterize heparin binding to interleukin-12 (IL-12) and determine the mechanism(s) by

140 Sustained intratumoral delivery of interleukin-12 (IL-12) and granulocyte macrophage colony

141 IFN-gamma)-producing cells in the absence of interleukin-12 (IL-12) and IFN-gamma.

142 H. pylori induced interleukin-12 (IL-12) and IL-10 through TLR4/MyD88 sign

143 populations of uNK cells were activated with interleukin-12 (IL-12) and IL-15, and conditioned media

144 ceptor engagement but not following combined interleukin-12 (IL-12) and IL-18 stimulation.

145 Conversely, PI3Ks negatively regulated interleukin-12 (IL-12) and IL-18-induced IFN-gamma by mo

146 Interleukin-12 (IL-12) and IL-23 are heterodimeric cytok

147 enance of Th1 and Th17 cells, by stimulating interleukin-12 (IL-12) and IL-23 production, but inhibit

148 Tlr7(-/-) mice and macrophages had reduced interleukin-12 (IL-12) and IL-23 responses after WNV inf

149 The relative contributions of interleukin-12 (IL-12) and IL-23 to viral pathogenesis h

150 R or M51R-F vector induced the production of interleukin-12 (IL-12) and IL-6 and increased surface ex

151 aracterized by the significant production of interleukin-12 (IL-12) and IL-6.

152 mice produced significantly higher levels of interleukin-12 (IL-12) and interferon gamma (IFN-gamma)

153 triggers then actively regulates host innate interleukin-12 (IL-12) and interferon-gamma (IFN-gamma)

154 We determined that interleukin-12 (IL-12) and interferon-gamma (IFN-gamma)

155 hat brief stimulation of memory T cells with interleukin-12 (IL-12) and interleukin-18 (IL-18) result

156 activation by suppressing the production of interleukin-12 (IL-12) and nitric oxide.

157 cells from BR mice respond to the virus with interleukin-12 (IL-12) and those from PE mice with IL-10

158 during primary F. tularensis infections, and interleukin-12 (IL-12) appears to be an essential coacti

159 inistration of inactivated LVS together with interleukin-12 (IL-12) as an adjuvant.

160 fection site tissues of normal mice produced interleukin-12 (IL-12) but not IL-10 and were characteri

161 Additionally, secretion of interleukin-12 (IL-12) by CD8alpha(+) DCs suggests a rol

162 udies have shown that mucosal application of interleukin-12 (IL-12) can stimulate elevated secretory

163 compound 37 that showed good TYK2 enzyme and interleukin-12 (IL-12) cell potency, as well as acceptab

164 pneumoniae respiratory disease severity with interleukin-12 (IL-12) concentrations in respiratory sec

165 h multigenic SIV plasmid DNA with or without interleukin-12 (IL-12) DNA or IL-15 DNA.

166 Herein, we demonstrate that interleukin-12 (IL-12) enhanced and sustained antigen an

167 Interleukin-12 (IL-12) has emerged as one of the most po

168 oma cell lines blocked the production of the interleukin-12 (IL-12) in human monocyte-derived dendrit

169 ttle is known about the role of the cytokine interleukin-12 (IL-12) in Pneumocystis pneumonia or its

170 Secretion of IFN-gamma is stimulated by interleukin-12 (IL-12) in the brain, as neutralization o

171 ly demonstrated that NK cells activated with interleukin-12 (IL-12) in the presence of immobilized Ig

172 Interleukin-12 (IL-12) is a pleiotropic cytokine that is

173 Interleukin-12 (IL-12) is a potent T(H)1 cytokine with r

174 Interleukin-12 (IL-12) is a powerful cytokine that activ

175 Interleukin-12 (IL-12) is critical for resistance to Tox

176 tokine receptor-deficient mice, we show that interleukin-12 (IL-12) is indispensible for mouse cytome

177 ivation of the cells with either recombinant interleukin-12 (IL-12) or IL-18.

178 ion, GSH depletion and the downregulation of interleukin-12 (IL-12) p40 mRNA were correlated with the

179 expression levels of MHC class II and higher interleukin-12 (IL-12) p40 production upon rickettsial i

180 less activation and decreased production of interleukin-12 (IL-12) p40.

181 e production of the proinflammatory cytokine interleukin-12 (IL-12) p40.

182 cktail, elicited type I interferon (IFN) and interleukin-12 (IL-12) p70 production and the appearance

183 h)17 cytokines gamma interferon (IFN-gamma), interleukin-12 (IL-12) p70, tumor necrosis factor alpha

184 ng the ability of dendritic cells to produce interleukin-12 (IL-12) p70.

185 nts contingent upon T cell receptor (TCR) or interleukin-12 (IL-12) plus IL-18 signaling.

186 K cell activation was controlled by systemic interleukin-12 (IL-12) produced by Batf3-dependent dendr

187 ined, we have previously shown that systemic interleukin-12 (IL-12) production is suppressed during c

188 s to intracellular pathogens in part through interleukin-12 (IL-12) production, although the relative

189 Since CD40 signaling contributes to interleukin-12 (IL-12) production, we examined IL-12 fro

190 nocytes were the primary cellular sources of interleukin-12 (IL-12) production.

191 ust splenic gamma interferon (IFN-gamma) and interleukin-12 (IL-12) recall responses with negligible

192 ever, inborn errors in STAT4, which controls interleukin-12 (IL-12) responses, have not yet been repo

193 ge colony-stimulating factor (GM-CSF) but no interleukin-12 (IL-12) responses.

194 major parasites prime human DC for efficient interleukin-12 (IL-12) secretion.

195 1-beta/CCL4, MIG/CXCL9, and severe defect of interleukin-12 (IL-12) secretion.

196 Specifically, we found that interleukin-12 (IL-12) signaling shortly after immunizat

197 ed to cross-prime CD8(+) T cells and produce interleukin-12 (IL-12) that promotes cytotoxicity.

198 The ability of exogenous interleukin-12 (IL-12) to elicit protective innate immun

199 The cytokine interleukin-12 (IL-12) was thought to have a central rol

200 ted a significant and chronic suppression of interleukin-12 (IL-12), a key host defense cytokine.

201 Analysis of the production of interleukin-12 (IL-12), alpha interferon (IFN-alpha), an

202 had YAHL and measured interleukin-2 (IL-2), interleukin-12 (IL-12), and interferon-gamma (IFN-gamma)

203 tumor necrosis factor alpha (TNF-alpha) and interleukin-12 (IL-12), and promotes systemic colonizati

204 Antibody-based neutralization of interleukin-12 (IL-12), but not IL-10, produced by M1 ma

205 oduction of gamma interferon (IFN-gamma) and interleukin-12 (IL-12), followed by a protective T cell

206 ficient animals, which are unable to produce interleukin-12 (IL-12), have a serious defect in expansi

207 NK cells differentiate after activation with interleukin-12 (IL-12), IL-15, and IL-18, exhibit potent

208 This study explored the role of interleukin-12 (IL-12), IL-23, and the regulatory cytoki

209 different components of the pathway such as interleukin-12 (IL-12), IL-23, IL-17A, and IL-17RA have

210 ed significantly greater dendritic cell (DC) interleukin-12 (IL-12), IL-27, and IL-10 immunity than M

211 , CD80, and CD86 as well as the secretion of interleukin-12 (IL-12), IL-6, and type I IFN.

212 and other proinflammatory cytokines, such as interleukin-12 (IL-12), interferon gamma (IFN-gamma), an

213 here they induce inflammatory DCs to produce interleukin-12 (IL-12), thereby promoting type 1 polariz

214 Consequently, adult CD11b(+) mDCs produced interleukin-12 (IL-12), which prevented Th2 cell develop

215 on (IFN-gamma) in an antigen-independent and interleukin-12 (IL-12)- and IL-18-dependent manner withi

216 Experiments in interleukin-12 (IL-12)-/- and IL-4-/- mice, in which pol

217 porated recombinant DNA (rDNA) along with an interleukin-12 (IL-12)-expressing plasmid (EP rDNA plus

218 c antigen through T-cell receptor (TCR)- and interleukin-12 (IL-12)-mediated signals.

219 ed the use of monocyte-derived, mature, high-interleukin-12 (IL-12)-producing type 1 polarized dendri

220 ion 4 (Stat4) and T-bet are required for the interleukin-12 (IL-12)-stimulated development of T helpe

221 t expression of the proinflammatory cytokine interleukin-12 (IL-12).

222 e phenotype when cultured in the presence of interleukin-12 (IL-12).

223 ucing NK cells that had been stimulated with interleukin-12 (IL-12)/IL-15.

224 on on monocytes and its regulatory effect on interleukin-12 (IL-12)/IL-23 production by CD14(+) monoc

225 ated liposomal doxorubicin (20 mg/m(2)) plus interleukin-12 (IL-12; 300 ng/kg subcutaneously twice we

226 gamma(1)34.5-deleted HSV-1 expressing murine interleukin-12 (IL-12; M002) prolonged survival of immun

227 egulation of CD40 or secretion of cytokines (interleukin 12 [IL-12], IL-10, tumor necrosis factor alp

228 umor necrosis factor alpha [TNF-alpha]; Th1, interleukin-12 [IL-12] and gamma interferon [IFN-gamma];

229 es (tumor necrosis factor alpha [TNF-alpha], interleukin-12 [IL-12], gamma interferon [IFN-gamma], an

230 urface receptors, cytokines, and chemokines (interleukin-12 [IL-12], IL-2, IL-1alpha, IL-1beta, IL-6,

231 donor T cells while releasing cytokines (eg, interleukin-12 [IL-12], IL-23, IL-6, IL-27, IL-10, trans

232 aneously proliferated ex vivo in a cytokine (interleukin-12 [IL-12]/IL-9/IL-15)-dependent manner, whi

233 on inhibitory factor]), cluster 3 (n=77; IL [interleukin]-12, IL-17, IL-10, IL-7, VEGF [vascular endo

234 ceptibility is heritable and linked to lower interleukin 12 (IL12) levels, which can also result from

235 ells and natural killer cells in response to interleukin 12 (IL12).

236 Interleukin-12 (IL12) is an important cytokine that link

237 3 and interleukin 4 and augmented levels of interleukin 12 in bronchoalveolar lavage fluid.

238 in T cells and found that it was induced by interleukin-12 in human and mouse T cells in a Stat4-dep

239 phocytes during viral infections and produce interleukin-12 in response to pathogens.

240 ild-type mice, as well as copious amounts of interleukin-12, indicating that Ym1-secreting p47(phox-/

241 As in the presence of a low concentration of interleukin-12 induced CD69 expression, interferon-gamma

242 nt selective elimination driven, in part, by interleukin-12-induced intrinsic expression of the Th1-c

243 STAT4 has a prominent role in mediating interleukin-12-induced T-helper cell type 1 lineage diff

244 sed production of proinflammatory cytokines (interleukin-12, interferon-gamma) was observed.

245 her admission serum levels of interleukin-2, interleukin-12, interferon-gamma, and tumor necrosis fac

246 ient, while another had functional defect in interleukin-12/interferon-gamma axis.

247 nterleukin-6, interleukin-9, interleukin-10, interleukin-12, interleukin-13, tumor necrosis factor-al

248 factor-alpha, interleukin-6, interleukin-10, interleukin-12, interleukin-17) at day 1 and day 8.

249 plified the effects of lipopolysaccharide on interleukin-12, interleukin-23, and matrix metalloprotei

250 tcome of anti-tumor necrosis factor and anti-interleukin-12/interleukin-23 treatment on SB and coloni

251 nterleukin-6, interleukin-8, interleukin-10, interleukin-12/interleukin-23p40, interleukin-13, interl

252 hen administered to Cryptosporidium-infected interleukin 12 knockout mice at 8-15 mg/kg/d for 1 week.

253 Interleukin 12-mediated polarization of CSF clones induc

254 w)CD56(dim) NK cells because of differential interleukin-12-mediated STAT4 phosphorylation.

255 ls of HLA-I with activated NKp30/MAPK/IL-12 (interleukin-12) or IL-2 (interleukin-2) pathway was susc

256 ded on interleukin-23 p19 secretion, whereas interleukin-12 p35 secretion controlled wasting disease

257 or and decreased levels of interferon gamma, interleukin 12 p40, interleukin 12 p70, and interleukin

258 ased levels of gamma interferon (IFN-gamma), interleukin-12 p40 (IL-12p40), and IL-2.

259 ct the events that lead to the production of interleukin-12 p40 (IL-12p40), which is required for res

260 d production of the proinflammatory cytokine interleukin-12 p40 through GPR84.

261 r (EGF), vascular endothelial growth factor, interleukin-12 (p40/70), and regulated on activation, no

262 els of interferon gamma, interleukin 12 p40, interleukin 12 p70, and interleukin 10 compared with con

263 duction of proinflammatory cytokines such as interleukin-12 p70 in DCs, but did not alter levels of m

264 enhanced their production of type I IFN and interleukin-12 (p70), augmented their capacity to proces

265 kin 17 and cytokines in the interferon-gamma/interleukin 12 pathway.

266 hed for complement cascade genes and for the interleukin-12 pathway.

267 (EP) or codelivered with a plasmid encoding interleukin-12 (pIL-12).

268 protein or with DNA for SIV genes and rhesus interleukin-12 plus SIV gp120 protein.

269 -/-Tc12) OT-1 effectors, differentiated with interleukin-12 present, are hyperproliferative in vitro,

270 toxic T cells and natural killer cells), and interleukin 12 production by antigen-presenting cells co

271 It enhances interleukin 12 production by macrophages, and several of

272 ount their discovery of how pathogen-induced interleukin 12 production leads to T(H)1 T cell polariza

273 ng in dendritic cells, which was crucial for interleukin 12 production through the phosphorylation of

274 d DC activation as demonstrated by decreased interleukin-12 production and attenuated expression of a

275 gondii profilin (TgPRF) and is required for interleukin-12 production and induction of immune respon

276 ubset is a prominent source of IFN-alpha and interleukin-12 production and should be further evaluate

277 e neoplastic lesions and increased levels of interleukin-12 production by the DC.

278 tigen-presenting cells, leading to increased interleukin-12 production in splenocytes.

279 d by high CD40 surface expression as well as interleukin-12 production, which are frequently seen in

280 We show here that interleukin-12 receptor beta1 (IL-12Rbeta1)-mediated sig

281 (PBMCs) and inflamed lungs, the majority of interleukin-12 receptor beta1 (IL12RB1) mRNAs contain a

282 High expression of tumor interleukin-12 receptor beta2 (IL-12Rbeta2) was associat

283 activate dendritic cells in vitro leading to interleukin-12 release.

284 ing effector cytokines, interferon-alpha and interleukin-12, respectively, in response to Toll-like r

285 t stimulatory cytokines interferon-alpha and interleukin-12, respectively.

286 receptor monoclonal antibody or recombinant interleukin 12 restored a robust anti-parasite TH1 respo

287 ctivated transcription of the genes encoding interleukin 12 subunit p40 (IL-12p40), IL-12p35 and IL-2

288 ion proteins based on antibody fragments and interleukin-12 subunit mutants.

289 roduced less tumor necrosis factor alpha and interleukin 12 than wild-type cells upon stimulation wit

290 3-/- neonates had a lower ability to produce interleukin-12 than their wild-type littermates and lowe

291 has been shown to inhibit the production of interleukin-12, the cytokine that is pivotal in establis

292 leukin-8, interleukin-10, interleukin-1beta, interleukin-12, tumor necrosis factor-alpha, and interfe

293 The cytokines interleukin-1beta, interleukin-12, tumor necrosis factor-alpha, and reactiv

294 We now show that interleukin-12, type I interferon, and transforming grow

295 e, we found that CD83, CD80, CD86, CD40, and interleukin-12 upregulation were significantly impaired

296 ytes, to sites of bacteria propagation where interleukin-12 was expressed in the spleen.

297 interferon, tumor necrosis factor alpha, and interleukin-12) were not necessary for E. muris-induced

298 atory cytokines, including interleukin 6 and interleukin 12, were significantly lower in the bronchoa

299 atory and proinflammatory mediators, such as interleukin-12, while downregulating coinhibitory PD-L1

300 eron-gamma, tumor necrosis factor-alpha, and interleukin-12) within atherosclerotic lesions and splee